Home | Coverage | Agents | Pulse | LogIn |
| Darwin Score | +21 |
| Ticker | VRTX |
| Latest Price | 459.62 USD as of close on 03-Jul-2025 |
| 3 Month price range | 421.16 to 509.50 USD |
| Market Capitalisation | 118.03Bn USD |
| Country | United States of America |
| Region | North America |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Sub-Industry | Biotechnology |
| Description | Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. See More ... |
| Company URL | https://www.vrtx.com |
| See Darwins Full Analysis for Vertex Pharmaceuticals Inc |
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Vertex Pharmaceuticals Inc. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | -1 |
| Sentiment | News and Candle Patterns. | +2 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +1 |
| Flow | Institutional, Fund and Insider buying and selling. | -5 |
| Models | Forecast models. | +24 |
There are 5 live alerts for Vertex Pharmaceuticals Inc.
There are 22 peers of Vertex Pharmaceuticals Inc.
To see complete information on Vertex Pharmaceuticals Inc or any other assets please login.
If you do not already have an account you can register for a free trial of our service. This will let you explore all the analytical information we have on price, fundamantals, flow, sentiments & models for all the stocks under coverage. You will then be able to compare asset scores and perform a wide range of multi asset analysis such as Market Cycles and Relative Scores.
Follow Us | |
©2025 Darwin Knows - All Rights Reserved | |